- Home
- ANAB vs ACEL Comparison
ANAB vs ACEL Comparison
Compare ANAB & ACEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- ACEL
- Stock Information
- Founded
- ANAB 2005
- ACEL 2009
- Country
- ANAB United States
- ACEL United States
- Employees
- ANAB N/A
- ACEL N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- ACEL Services-Misc. Amusement & Recreation
- Sector
- ANAB Health Care
- ACEL Consumer Discretionary
- Exchange
- ANAB Nasdaq
- ACEL Nasdaq
- Market Cap
- ANAB 759.5M
- ACEL 818.8M
- IPO Year
- ANAB 2017
- ACEL N/A
- Fundamental
- Price
- ANAB $22.23
- ACEL $11.23
- Analyst Decision
- ANAB Buy
- ACEL Buy
- Analyst Count
- ANAB 10
- ACEL 1
- Target Price
- ANAB $42.25
- ACEL $16.00
- AVG Volume (30 Days)
- ANAB 559.5K
- ACEL 341.0K
- Earning Date
- ANAB 05-05-2025
- ACEL 05-05-2025
- Dividend Yield
- ANAB N/A
- ACEL N/A
- EPS Growth
- ANAB N/A
- ACEL N/A
- EPS
- ANAB N/A
- ACEL 0.49
- Revenue
- ANAB $111,872,000.00
- ACEL $1,253,067,000.00
- Revenue This Year
- ANAB N/A
- ACEL $9.02
- Revenue Next Year
- ANAB $9.72
- ACEL $4.84
- P/E Ratio
- ANAB N/A
- ACEL $22.83
- Revenue Growth
- ANAB 387.20
- ACEL 6.28
- 52 Week Low
- ANAB $12.21
- ACEL $9.02
- 52 Week High
- ANAB $41.31
- ACEL $12.96
- Technical
- Relative Strength Index (RSI)
- ANAB 62.32
- ACEL 50.32
- Support Level
- ANAB $20.50
- ACEL $11.14
- Resistance Level
- ANAB $22.84
- ACEL $11.37
- Average True Range (ATR)
- ANAB 1.28
- ACEL 0.18
- MACD
- ANAB 0.12
- ACEL -0.06
- Stochastic Oscillator
- ANAB 83.24
- ACEL 16.97
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About ACEL Accel Entertainment Inc.
Accel Entertainment Inc is a distributed gaming and local entertainment operator in the United States. It is engaged in the installation, maintenance, operation, and servicing of gaming terminals and related equipment, redemption devices that disburse winnings and contain automated teller machine (ATM) functionality, and amusement devices in authorized non-casino locations such as restaurants, bars, taverns, convenience stores, liquor stores, truck stops, and grocery stores. The Company also operates stand-alone ATMs in gaming and non-gaming locations. It generates revenue from Net gaming, Amusement, Manufacturing, ATM fees, and others.